Skip to main content
SpringerLink
Log in

Androgen Receptor and Interleukin-6 Signaling In PCA Progression

  • Chapter
Hormonal Carcinogenesis IV

  • 598 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Irvine RA, Yu MC, Ross RK, et al (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937–1940.

    PubMed  CAS  Google Scholar 

  2. Masiello D, Cheng S, Bubley GJ, et al (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277:26321–26326.

    Article  PubMed  CAS  Google Scholar 

  3. Horoszewicz JS, Leong SS, Kawinski E, et al (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818.

    PubMed  CAS  Google Scholar 

  4. Navone NM, Olive M, Ozen M, et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493–2500.

    PubMed  CAS  Google Scholar 

  5. Cronauer MV, Nessler-Menardi C, Klocker H, et al (2000) Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82:39–45.

    Article  PubMed  CAS  Google Scholar 

  6. Heisler LE, Evangelou A, Lew AM, et al (1997) Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126:59–73.

    Article  PubMed  CAS  Google Scholar 

  7. Quarmby VE, Beckman WCJ, Cooke DB, et al (1990) Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50:735–739.

    PubMed  CAS  Google Scholar 

  8. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189–193.

    PubMed  Google Scholar 

  9. Hobisch A, Culig Z, Radmayr C, et al (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068–3072.

    PubMed  CAS  Google Scholar 

  10. Quarmby VE, Yarbrough WG, Lubahn DB, et al (1990) Autologous downregulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4:22–28.

    Article  PubMed  CAS  Google Scholar 

  11. Kokontis J, Takakura K, Hay N, et al (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566–1573.

    PubMed  CAS  Google Scholar 

  12. Culig Z, Hoffmann J, Erdel M, et al (1999) Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242–251.

    Article  PubMed  CAS  Google Scholar 

  13. Zegarra-Moro OL, Schmidt LJ, Huang H, et al (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008–1013.

    PubMed  CAS  Google Scholar 

  14. Visakorpi T, Hyytinen E, Koivisto P, et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Gen 9:401–406.

    Article  CAS  Google Scholar 

  15. Palmberg C, Koivisto P, Kakkola L, et al (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992–1995.

    Article  PubMed  CAS  Google Scholar 

  16. Gregory CW, Hamil KG, Kim D, et al (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718–5724.

    PubMed  CAS  Google Scholar 

  17. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, et al (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 17:534–540.

    Article  Google Scholar 

  18. Newmark JR, Hardy DO, Tonb DC, et al (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319–6323.

    Article  PubMed  CAS  Google Scholar 

  19. Culig Z, Hobisch A, Cronauer MV, et al (1993) Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550.

    Article  PubMed  CAS  Google Scholar 

  20. Wong CI, Kelce WR, Sar M, et al (1995) Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270:19998–20003.

    Article  PubMed  CAS  Google Scholar 

  21. Taplin ME, Bubley GJ, Ko YJ, et al (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511–2515.

    PubMed  CAS  Google Scholar 

  22. Haapala K, Hyytinen ER, Roiha M, et al (2001) Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 81:1647–1651.

    PubMed  CAS  Google Scholar 

  23. Marcelli M, Ittmann M, Mariani S, et al (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60:944–949.

    PubMed  CAS  Google Scholar 

  24. Taplin ME, Bubley GJ, Shuster TD, et al (1995) Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398.

    Article  PubMed  CAS  Google Scholar 

  25. Culig Z, Hobisch A, Cronauer MV, et al (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474–5478.

    PubMed  CAS  Google Scholar 

  26. Craft N, Shostak Y, Carey M, et al (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280–285.

    Article  PubMed  CAS  Google Scholar 

  27. Yeh S, Lin HK, Kang HY, et al (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458–5463.

    Article  PubMed  CAS  Google Scholar 

  28. Tsihlias J, Zhang W, Bhattacharya N, et al (2000) Involvement of p27 (Kip1) in G1 arrest by high dose 5alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19:670–679.

    Article  PubMed  CAS  Google Scholar 

  29. Hofman K, Swinnen JV, Verhoeven G, et al (2001) E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 283:97–101.

    Article  PubMed  CAS  Google Scholar 

  30. Sadar MD, Gleave ME (2000) Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 60:5825–5831.

    PubMed  CAS  Google Scholar 

  31. Nazareth LV, Weigel NL (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900–7.

    Article  PubMed  CAS  Google Scholar 

  32. Twillie DA, Eisenberger MA, Carducci MA, et al (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542–549.

    Article  PubMed  CAS  Google Scholar 

  33. Adler HI, McCurdy MA, Kattan MW, et al (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 161:182–187.

    Article  PubMed  CAS  Google Scholar 

  34. Chung TD, Yu JJ, Spiotto MT, et al (1999) Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199–207.

    Article  PubMed  CAS  Google Scholar 

  35. Giri D, Ozen M, Ittmann M (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159:159–165.

    Google Scholar 

  36. Yang L, Wang L, Lin HK, et al (2003) Interleukin-6 differentially regulates androgen receptor transactivation via P13K-Akt, STAT3, MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305:462–469.

    Article  PubMed  CAS  Google Scholar 

  37. Hobisch A, Eder IE, Putz T, et al (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640–4645.

    PubMed  CAS  Google Scholar 

  38. Godoy-Tundidor S, Hobisch A, Pfeil K, et al (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356–2361.

    PubMed  CAS  Google Scholar 

  39. Mori S, Murakami-Mori K, Bonavida B (1999) Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res 19:1011–1015.

    PubMed  CAS  Google Scholar 

  40. Degeorges A, Tatoud R, Fauvel Lafeve F, et al (1996) Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68:207–214.

    Article  PubMed  CAS  Google Scholar 

  41. Hobisch A, Ramoner R, Fuchs D, et al (2001) Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res 7:2941–2948.

    PubMed  CAS  Google Scholar 

  42. Steiner H, Godoy-Tundidor S, Rogatsch H, et al (2003) Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162:655–663.

    PubMed  CAS  Google Scholar 

  43. Spiotto MT, Chung TD 2000 STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42:88–98.

    Article  PubMed  CAS  Google Scholar 

  44. Chung TD, Yu JJ, Kong TA, Spiotto MT, et al (2000) Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 42:1–7.

    Article  PubMed  CAS  Google Scholar 

  45. Comuzzi B, Lambrinidis L, Rogatsch H, et al (2003) The transciptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen-and anti-androgen-induced androgen receptor function. Am J Pathol 162:233–241.

    PubMed  CAS  Google Scholar 

  46. Gnanapragasam VJ, Leung HY, Pulimood AS, et al (2001) Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928–1936.

    Article  PubMed  CAS  Google Scholar 

  47. Halkidou K, Gnanapragasam VJ, Mehta PB, et al (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22:2466–2477.

    Article  PubMed  CAS  Google Scholar 

  48. Gregory CW, He B, Johnson RT, et al (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315–4319.

    PubMed  CAS  Google Scholar 

  49. Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517–5521.

    Article  PubMed  CAS  Google Scholar 

  50. Miyamoto H, Yeh S, Wilding G, et al (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379–7384.

    Article  PubMed  CAS  Google Scholar 

  51. Wang LG, Ossowski L, Ferrari AC (2001) Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61:7544–7551.

    PubMed  CAS  Google Scholar 

  52. Smith PC, Keller ET (2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Innsbruck, Innsbruck, Austria

    Zoran Culig & Sonia Godoy-Tundidor

Authors
  1. Zoran Culig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannes Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonia Godoy-Tundidor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Comuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georg Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alfred Hobisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, The University of Kansas Medical Center, 3901 Rainbow Boulevard, 2010 Breidenthal, Kansas City, KS, 66160-7417

    Jonathan J. Li (Profesor of Pharmacology, Toxicology and Therapeutics and Director) & Sara A. Li (Associate Research Professor of Pharmacology, Toxicology and Therapeutics) (Profesor of Pharmacology, Toxicology and Therapeutics and Director) &  (Associate Research Professor of Pharmacology, Toxicology and Therapeutics)

  2. Departmento de Patologia, Facultad de Medicina y Odontologia, Camino de Vera s/n, Valencia, 46071, Spain

    Antonio Llombart-Bosch (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Culig, Z., Steiner, H., Godoy-Tundidor, S., Comuzzi, B., Bartsch, G., Hobisch, A. (2005). Androgen Receptor and Interleukin-6 Signaling In PCA Progression. In: Li, J.J., Li, S.A., Llombart-Bosch, A. (eds) Hormonal Carcinogenesis IV. Springer, Boston, MA. https://doi.org/10.1007/0-387-23761-5_18

Download citation

  • DOI: https://doi.org/10.1007/0-387-23761-5_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-23783-1

  • Online ISBN: 978-0-387-23761-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation